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Abstract 
Infections caused by septicemic strains of Salmonella are significant animal health as well as food 
safety concerns for the North American swine industry. Among the various strategies to control 
these mfections at the herd level, development of vaccines are attractive alternatives. In this 
study, based on previous studies of immune response to various protems following natural and 
experimental infections of pigs by Salmonella, we designed a subumt slow delivery vaccme and 
tested it m an experimental model of Infection. The selected 1mmunogen1c protem was cloned 
and purified by chromatography. The purified protein was then incorporated m PLGA (a polymer 
that is slowly degraded within the ammal's gastro Intestinal system) m1crospheres and g1ven orally 
once to groups of p1gs (n=8) while control animals (n=8) rece1ved only PBS. An1mals were 
challenged orally 4 weeks after the vaccmation w1th 1 0 8 cells of a virulent strains of Salmonella 
Typhimurium. An1mals were examined twice a day and climcal signs evaluated using a 
predetermmed sconng gnd. Pigs were sacrificed 12 days later and bacterial cultures of vanous 
organs, electron m1croscopy and evaluation of lgA response by ELISA were performed. No 
Significant difference was found at bactenology and ELISA but marked differences 1n climcal s1gns 
were observed between vaccinated and non vaccinated animals. None of vaccmated an1mals 
showed fever exceedmg 40°C while it was observed in 5 out of 8 non vaccinated Only one of 
vaccmated p1gs showed mild diarrhea wh1le severe diarrhea was observed m all control ammals 
Different s1zes of m1crospheres were observed m intestmal crypts of vacc1nated ammals at 
electron m1croscopy We concluded that th1s vaccine can protect p1gs aga1nst climcal s1gns 
associated with expenmental infection by Salmonella Typh1munum. 
Introduction 
Although Salmonella IS, m pigs, most often associated w1th sub-clinical 1nfect1ons, the Typhimurium 
serovar can cause severe clinical s1gns such as septicaemia and may as well result m mortalities 
that can have significant econom1cal 1mpacts 1n affected herds. This serovar is often among the 
most important serovar recovered from humans and 11 IS therefore cnllcal to reduce the number of 
affected ammals. When herds are affected by climcal outbreaks of S. Typh1munum, 11 was shown 
that the bactena IS present in most an1mals/pens and environmental samples (Letellier and al 1999), 
increas1ng the likelihood of meat contammat1on. It is therefore important to control these infections 
at the herd level both for productivity and food safety po1nt of v1ews Since the host-adapted serovar 
Choleraesuis was in the past, and IS st1ll, assoc1ated w1th s1m1lar clin1cal s1gns, most vacc1nes, live or 
autogenous, were developed to protect pigs against this serovar Nevertheless, a few live vacc1nes 
were proposed to reduce S Typh1munum clinical s1gns (Roesler et al, 2004) In this study, we 
report the development of a sub-umt slow delivery vaccme aga1nst S Typh1munum 1n p1gs and 
results of a pre-clinical protect1on trial using an expenmental model of mfecllon 
Material and Methods 
Selection of 1mmunogemc protems. The protein to be included in vaccine was selected by 
western blots us1ng vanous strains of S Typh1munum as ant1gens and antisera. Bacteria were 
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•Wn in different conditions (low and high osmolarity, low iron, low pH, ... ) to ensure that the 
~eted protein would be expressed in various phases of infection. The antisera used to detect 
nunogenic proteins were recovered from over a hundred of animals that survived episodes 
1ical salmonellosis in various herds. The selected protein (p 37) was recognized by all antisera 
j was expressed in al types of growth conditions. 
rification of protein. The selected protein was sequenced and cloned into E. coli M 15 using 
R®2.1 ::gapAREZ as vector. Using the histidine tail the protein was purified by affinity 
·omatography (FPLC). 
;rospheres production. The selected matrix was a co-polymer of ( poly (DL-Iactic-co-glycolic) 
d) (PLGA), a non toxic, non teratogenic, FDA approved molecule. The delivery rates are 
1trolled by the relative proportion of copolymers. The end products of this polymer are C02 
0 . Moreover, it is known that 11 j.Jm and less microspheres are well absorbed by intestinal 
Is at Payers patches level (Tabata et al., 1996). This compound also possesses adjuvant 
>perties (lgartua et al., 1998). The P37 protein was incorporated into PLGA in a pre-determined 
io with co-incorporation of albumin to improve P37 incorporation rates. The resulting 
:::rospheres were lyophilized until the protection trials. 
)tection trial. Groups of 8 cross-bred Salmonella negative pigs were administered orally 2 cc of 
::rospheres or PBS (control pigs) at 3 weeks of age. At 7 weeks of age, animals were given 
lily 10 8 cells of a virulent Salmonella Typhimurium DT 104 strains. Pigs were examined twice 
jay for 12 days using a pre-determined evaluation grid (the sum of clinical signs scores and 
1rrhea scores (on 4 levels of severity each) and then sacrificed. At necropsy, bacterial cultures 
d Salmonella counts in feces and internal organs were performed. Washes of intestinal mucus 
·re also performed and lgA production was assessed using an ELISA, adapted from a 
~viously described procedures (Cote et al, 2004 ). Finally, electron microscopy was done on 
1all intestines of necropsied animals to check for the presence of microspheres in intestinal 
•pts. 
~suits 
imals that received the microsphere vaccine had clearly less clinical signs compared to the 
ntrol group (figure 1 ). Only one of vaccinated animals showed a mild diarrhea while diarrhea, 
• en severe, was observed in all control animals. None of vaccinated animals had temperature 
er 40° C while it was observed in 5 out of 8 control pigs. Although a trend to higher lgA levels 
~s observed in vaccinated pigs, no statistical diffence was observed between to groups of 
1mals. Electron microscopy revealed the presence of microspheres in intestinal crypts and 
latine tonsils 2 days after immunization (data not shown) and 12 days after the experimental 
allenge (figure 2), more than 5 weeks after vaccination. It was not possible to observe 
ltistically significant reduction of bacterial counts in tissues of both groups of animals. 
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Figure 1. : Mean scores of clinical s1gns observed in pigs vacc~nated (green) with P37 
incorporated PLGA m1crospheres following a challenge w1th Salmonella Typhimunum DT104 strain 
compared to control group (in yellow). 
Figure 2. Electron m1croscopy of 1ntest~nal crypts (A) and palatine tons1ls (C) of vacc~nated and 
control pigs (B,D) 
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Discussion 
Use of sub-unit vaccines can be beneficial to avoid undesirable effects seldom seen with live 
vaccine In addition , when the selected antigen IS embedded within an appropriate matrix, it may 
be delivered into the host gradually, avoiding repetitive vaccine admintstrat1ons. Results obtained 
in th1s study suggest that co-polymer of PLGA can be use to protect immunogenic proteins in 
swine and to slowly deliver the antigens within the intestinal tract. Indeed, even 5 weeks after 
vaccine administration, it was possible to observe microspheres in the intestinal tract of p1gs 
suggest1ng that the vaccine will be efficiently delivered for a prolonged period of time. Moreover, 
the fact that the end products of th1s compounds are non toxic would eliminate any concern related 
to food safety. 
S1nce relatively high dosages of bacteria were used to ensure reproduction of clinical s1gns and 
given the low numbers of an1mals that were used, it was not unexpected to not observe significant 
difference 1n bactenal counts in various organs. Further studies with different experimental designs 
will have to be conducted to assess the ability of this vaccine to reduce shedding of Salmonella or 
to assess cross protection against other serovar. 
Conclusion 
Use of a subunit slow delivery vaccine composed of the P37 protein embedded within PLGA 
m1crospheres succeeded in protecting animals against an experimental infection by Salmonella 
Typh1murium. It is suggested to conduct further research to assess the efficacy of this vaccine to 
protect animals against the disease in field conditions or to reduce the carriage in sub-clintcal 
mfections. 
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